Subconjunctival bevacizumab for corneal neovascularization.
To describe whether subconjunctival bevacizumab decreases corneal neovascularization in patients with ocular surface inflammatory diseases. The study is a retrospective case series that includes 8 eyes of 7 patients with corneal neovascularization. Patients received 1-3 injections of 2.5 mg subconjunctival bevacizumab. Morphologic changes were assessed clinically by the same investigator at each visit. Subconjunctival bevacizumab was well-tolerated without obvious corneal side effects. All 8 eyes of the 7 patients showed a reduction in the neovascularized area. Subconjunctival bevacizumab may provide an additional strategy in improving vision or improving success of corneal grafts in these patients.